The adjustment follows a discussion with a prominent glaucoma surgeon regarding the impact of Glaukos' iDose device on the field of Minimally Invasive Glaucoma Surgeries (MIGS). The surgeon ...

Glaukos GKOS recently announced positive data from a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials evaluating its latest approved product, iDose TR.

Glaukos Corporation's shares have dropped 21 ... Given the strong success of iDose TR over the past 12 months, management is fully aware that momentum must be built on getting surgeons up to ...